Teladoc Health Files 8-K with Financial Updates

Ticker: TDOC · Form: 8-K · Filed: 2024-07-31T00:00:00.000Z

Sentiment: neutral

Topics: financial-results, operations, sec-filing

Related Tickers: TDOC

TL;DR

TDOC filed its 8-K on 7/31/24 with financial results - check it for the latest performance.

AI Summary

On July 31, 2024, Teladoc Health, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, providing an update on the company's performance for the period ending July 31, 2024. This report is crucial for investors to assess the company's current financial health and strategic direction.

Why It Matters

This 8-K filing provides investors with essential, up-to-date financial information and operational details for Teladoc Health, Inc., enabling informed investment decisions.

Risk Assessment

Risk Level: medium — 8-K filings are routine disclosures, but the specific financial details within can reveal significant positive or negative performance trends.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K filing?

The filing indicates it includes 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', providing an update on the company's financial performance.

When was this 8-K report filed with the SEC?

The report was filed on July 31, 2024.

What is the primary purpose of this 8-K filing for Teladoc Health, Inc.?

The primary purpose is to report on the company's results of operations and financial condition, as well as to file necessary financial statements and exhibits.

What is Teladoc Health, Inc.'s state of incorporation?

Teladoc Health, Inc. is incorporated in Delaware.

Where are Teladoc Health, Inc.'s principal executive offices located?

The principal executive offices are located at 2 Manhattanville Road, Suite 203, Purchase, NY 10577.

From the Filing

0001477449-24-000172.txt : 20240731 0001477449-24-000172.hdr.sgml : 20240731 20240731160523 ACCESSION NUMBER: 0001477449-24-000172 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240731 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240731 DATE AS OF CHANGE: 20240731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Teladoc Health, Inc. CENTRAL INDEX KEY: 0001477449 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043705970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37477 FILM NUMBER: 241161893 BUSINESS ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 BUSINESS PHONE: 2036352002 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 FORMER COMPANY: FORMER CONFORMED NAME: Teladoc, Inc. DATE OF NAME CHANGE: 20091123 8-K 1 tdoc-20240731.htm 8-K tdoc-20240731 FALSE 0001477449 0001477449 2023-07-25 2023-07-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) July 31, 2024 ___________________________________ Teladoc Health, Inc. (Exact name of registrant as specified in its charter) ___________________________________ Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-3705970 (I.R.S. Employer Identification No.) 2 Manhattanville Road Suite 203 Purchase , NY 10577 (Address of principal executive offices and zip code) ( 203 ) 635-2002 (Registrant's telephone number, including area code) ___________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock, par value $0.001 per share TDOC The New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02.    Results of Operations and Financial Condition. On July 31, 2024, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the second quarter of 2024. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in Item 9.01 hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference i

View on Read The Filing